Personalis reports 400% clinical test volume growth in 2025, guides $78-80M FY2026 revenue

Personalis, Inc.

2025-FY EPS reported -$0.91 vs consensus -$0.30 ▼ miss (-204.3%)

Clinical volume surged 400% YoY to 16,233 tests; Q4 sequential growth 41% to 6,183 tests.
Total FY2025 revenue $69.6M (down 18% YoY); clinical test revenue more than doubled to $2.0M.
Ended 2025 with ~$240M cash, including $109M net from ATM at $8.43/share average.
Secured Medicare coverage for breast and lung cancer surveillance; key catalyst for MRD.
FY2026 guidance: total revenue $78-80M, clinical revenue $10-11M (5x growth), net loss ~$105M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.